In this multi-centre trial, patients (n=291 from 6 centres) randomly receive a whole-body PET-CT scan to determine whether imaging assists in muscle-invasive urothelial carcinoma of the bladder staging. Each PET-CT scan needs to then be reviewed locally and centrally within 3-5 days of the scan.
QIPCM provided a de-identification and image transfer pipeline to each centre to anonymize all trial images before they leave each centre. Only anonymized images are sent to QIPCM, after which they are archived in our safe, secure, and backed-up PACS.
Access to these images are logged and made available only to permitted trial personnel. Central reviewers can thus log-in to the QIPCM platform to review trial images anytime, from anywhere with internet access to meet review deadlines.